Cellectar Biosciences reports 79.2% major response rate for iopofosine I 131 in Phase 2 Waldenström macroglobulinemia subset after BTK inhibitors

Cellectar Biosciences reported a 79.2% major response rate for iopofosine I 131 in a Phase 2 subset of Waldenström macroglobulinemia patients who had received prior BTK inhibitors.

Detected & updated continuously · Source: Nebula